Skip to main content

Pay Bill Portals

Our Tests
Our Services
- - Oncology
    - - SERVICES
        
        NateraCore Services
        
        Pharma Partnership
    - - FOR PATIENTS
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
        
        Contact Us
    - - FOR CLINICIANS
        
        Schedule Session With Client Services
        
        Oncology Portal
        
        Order a Test Kit
        
        Contact Us
  - Organ Health
    - - SERVICES
        
        NateraCore Services
        
        ProReach
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Contact Us
    - - FOR CLINCIANS
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - SERVICES
        
        NateraCore Services
        
        Constellation
    - - FOR PATIENTS
        
        Schedule a Genetic Information Session
        
        Pricing and Billing Information
        
        Women’s Health Portal
        
        Contact Us
    - - FOR CLINICIANS
        
        Order Tests and Track Status on NateraConnect
        
        View Patient Results on NateraConnect
        
        Contact Us
Patient Resources
- - Oncology
    - - LEARN
        
        Signatera
        Altera
        Empower
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule Session with Patient Coordinator
        
        Pricing and Billing Information
    - - CONNECT
        
        Contact Us
  - Organ Health
    - - LEARN
        
        Prospera
        Renasight
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule Blood Draw (Existing Patients)
        
        Schedule a Genetic Information Session
    - - CONNECT
        
        Contact Us
  - Women’s Health
    - - LEARN
        
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        View All Patient Resources
    - - EXISTING PATIENTS
        
        Schedule a Genetic Information Session
        
        Schedule Blood Draw (Existing Patients)
        
        Pricing and Billing Information
        
        Women’s Health Portal
    - - CONNECT
        
        Contact Us
Clinical Resources
- - Oncology
    - - CLINICAL RESOURCES
        
        Order Forms
        
        Signatera
        Signatera Publications
        Altera
        Empower
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        Signatera Research Pipeline
        
        BESPOKE CRC
        
        BESPOKE IO
    - - CONNECT
        
        Oncology Portal
        
        Contact Us
  - Organ Health
    - - CLINICAL RESOURCES
        
        Organ Health Publications
        Prospera
        Renasight
        View All Clinician Resources
    - - RESEARCH STUDIES
        
        ProActive Study
        
        PEDAL Study
        
        Trifecta Study
        
        MOTR Study
    - - CONNECT
        
        Organ Health Portal
        
        Contact Us
  - Women’s Health
    - - CLINICAL RESOURCES
        
        Women’s Health Publications
        Horizon
        Panorama
        Empower
        Vistara
        Anora
        Spectrum
        Natera Academy Provider Education Hub
        View All Clinician Resources
    - - RESEARCH STUDIES
    - - CONNECT
        
        Contact Us
Company
Search for:
Pay Bill

Portals
Search for:

Natera, Inc.

- Altera
- Anora
- Empower
- Horizon
- Panorama
- Prospera
- Renasight
- Signatera
- Spectrum
- Vistara
- Blog
- Videos
- Brochure
- Whitepaper
- Manual
- Poster
- Report
- Study
- Webinars
- Natera Academy

Recent Searches

Home
Panorama
Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome

Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome

Dar et al. 2022 AJOG publication

Previous Resource

Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation.

Dar et al. 2022 AJOG publication
Next Video

Panorama NIPT and Horizon Carrier Screen Patient Overview - Vietnamese

Related Content

4 days ago
Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort

Gilstrop Thompson, et al. OBSTETRICS & GYNECOLOGY 2024

Read More
11 days ago
22q11.2 Deletion Syndrome (DiGeorge): Its impact on families and why early detection matters

Watch Video
16 days ago
Genetic Counselor Awareness Day 2024

Introduction to Genetic Counseling Roles in Industry

Watch Video
about 1 month ago
Importance of high detection 22q screening

Dr. Sam Leonard, Sr. Medical Director (Natera), walks through how to appropriately consider the balance between high detection rates and screen positive rates when selecting a screen.

Watch Video
about 1 month ago
Importance of 22q screening and KOL testimonial

Dr. Blagowidow, OB Geneticist, talks about the importance of early prenatal 22q11.2 deletion syndrome (22q, formerly DiGeorge syndrome) screening and factors to consider when selecting a screen.

Watch Video
3 months ago
Fetal RhD NIPT: do all Rh negative patients need Rh immune globulin?

Watch Video
4 months ago
The evolution of NIPT: what comes next

In this talk, we will highlight how early, highly accurate prenatal screening optimizes outcomes for patients with 22q11.2 deletion syndrome, and review recently-published data from a large clinical v

Watch Video
6 months ago
Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Watch Video
6 months ago
Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk

Natera™'s Fetal RhD NIPT (noninvasive prenatal testing) is now available. The test is backed by the largest clinical validation study for fetal RhD in the US to date, and demonstrated 100 percent sens

Watch Video
6 months ago
Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Read More
9 months ago
It's time to screen routinely for 22q11.2 deletion syndrome: new evidence of improved outcomes with prenatal diagnosis

To manage pregnancies at high risk for 22q11.2 deletion syndrome (DS), prenatal and neonatal evaluation after high risk cfDNA screening is needed. Supplemental assessments and early intervention can i

Watch Video
Compassionate Care Application - Spanish

Read More
9 months ago
Carrier Manifestations in Pregnancy

Utility of carrier screening to inform management

Watch Video
Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from t

Martin et al. 2023 Prenat. Diagn

Read More
Natera Product Brochure

Read More
Validation of an Enhanced Version of a Single- Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Detection of Fetal Aneuploidies

Ryan A, Hunkapiller N, Banjevic M, et al. Fetal Diagn Ther 2016

Read More
Informatics-based, highly accurate, noninvasive prenatal paternity testing

Ryan A, Baner J, Demko Z, et al. Genet Med 2013

Read More
Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphismebased noninvasive prenatal test

Curnow KJ, Wilkins-Haug L, Ryan A, et al. Am J Obstet Gynecol 2015

Read More
Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fe

Norwitz ER, McNeill G, Kalyan A, et al. Journal of Clinical Medicine 2019

Read More
Re: Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate

Jelsema R, Demko ZP, Billing, PR. Ultrasound Obstet Gynecol. 2020

Read More

Return to Resource Library

© Natera, Inc.

Our Tests
Our Services
Patient Resources
Clinical Resources
- Resource Library
- Provider Portals
Company
Contact

Natera Licenses
IT Security Compliance
Natera Notice of Data Collection for California Residents
Privacy Practices
Privacy Policy
Terms of Use
Sitemap

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.